Latest:
Dr. Mauro on the Risks of Disease Progression in Myelofibrosis
Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Michael J. Pishvaian, MD, PhD
Latest:
Dr. Pishvaian on the Implications of the RATIONALE-306 Trial in ESCC
Michael Jon Pishvaian, MD, PhD, discusses the clinical implications of the phase 3 RATIONALE 306 trial and the adverse effects associated with immunotherapy in patients with advanced esophageal squamous cell carcinoma.
Michael J. Thirman, MD
Latest:
MRD Testing and the Role of Revumenib in Treatment Response
Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.
Michael K. Gould, MD, MS
Latest:
Dr. Gould on the Implications of the NELSON Trial in Lung Cancer
Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.
Michael Kent, DVM
Latest:
Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or Sarcoma
Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.
Michael L. Blute, MD
Latest:
Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC
Michael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).
Michael L. Wang, MD University of Texas MD Anderson Cancer Center
Latest:
Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell Therapy
Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.